Every article, presentation, spotlight, and news item we've tagged to Hallmarks of Aging.
Showing 193–216 of 225
Individuals with more problematic people in their close social networks exhibit accelerated biological aging, with each additional "hassler" associated with a 1.5% faster aging pace and approximately 9.5 months of additional biological age. This effect persists after controlling for demographic, occupational, and health factors, establishing social stress as a measurable driver of epigenetic aging.
ARPA-H is allocating $144 million through its PROSPR program to fund seven research teams testing interventions designed to extend healthspan in humans. The initiative addresses a critical gap in geroscience drug development by establishing early biomarkers and trial designs that can demonstrate functional benefit within one to three years rather than decades.
APOE2, a genetic variant associated with exceptional longevity, activates DNA repair pathways and resists cellular senescence in neurons, while APOE4 exhibits elevated DNA damage and senescence markers. This mechanism extends beyond lipid metabolism, explaining APOE2's protective effects against neurodegeneration.
Two conjugated polyunsaturated fatty acids, α-eleostearic acid and its methyl ester, demonstrated senolytic activity in cell cultures and mouse models across multiple tissues without systemic toxicity. The structural features of these compounds—particularly conjugation patterns and double-bond configuration—correlate with their ability to eliminate senescent cells, which accumulate with age and drive inflammatory cascades linked to chronic disease.
Juvenescence's PAI-1 inhibitor MDI-2517 completed Phase 1 trials, demonstrating safety and tolerability for a once-daily oral therapy targeting inflammation and fibrosis—processes central to aging and age-related disease. Genetic evidence suggests PAI-1 reduction correlates with approximately 10 years of extended lifespan, positioning this mechanism as a meaningful target for aging intervention.
Fibulin-5, an extracellular matrix protein that declines with age, maintains populations of fast-cycling skin cells through YAP signaling. Mice lacking fibulin-5 exhibit accelerated skin aging phenotypes, including loss of fast-cycling cells and compromised epidermal-dermal junction integrity, mirroring natural aging processes.
TGFβ signaling emerges as the primary tumor-promoting mechanism within senescent cells induced by platinum chemotherapy in ovarian and lung cancers. Targeting this pathway selectively could preserve the therapeutic benefit of chemotherapy while blocking its pro-tumor effects, addressing a critical vulnerability in current cancer treatment.
Terbinafine and miglustat, FDA-approved drugs, extend lifespan and healthspan by inducing mitochondrial stress responses through coordinated activation of ATFS-1 and DAF-16 pathways. This mechanism represents a distinct integration of mitochondrial and insulin signaling stress responses relevant to aging intervention.
Single-cell profiling of nearly 1,000 individuals demonstrates that immune aging follows distinct cellular and transcriptional trajectories between sexes, with female participants showing more pronounced cellular and molecular remodeling than males. This finding reveals that sex-based differences in immune function are not uniform across aging and must inform how we assess and support immune resilience across the lifespan.
Retinal protein signatures correlate with systemic aging markers and clinical traits in women, establishing the eye as a window into whole-body physiological age. These oculometric measures may enable earlier detection of aging-related dysfunction across multiple organ systems.
Urolithin A activates mitophagy—the removal of damaged mitochondria—and prevents age-related cognitive decline when initiated early, but fails to reverse existing cognitive impairment when treatment begins after decline has already occurred. This temporal dependency defines a critical window for intervention in age-related neurodegeneration.
Adherence to sustainable dietary patterns moderates the accelerated biological aging associated with particulate matter exposure, suggesting that dietary quality can partially offset environmental pollutant burden at the cellular level. This finding indicates a modifiable pathway through which nutritional intervention may counteract oxidative stress and inflammatory cascades triggered by air pollution.
ARPA-H has awarded $22 million to Linnaeus Therapeutics to test LNS8801, an oral drug designed to preserve physical and cognitive function in aging before decline occurs. The approach represents a shift from treating age-related disease toward maintaining the integrated capacities that sustain independence and resilience.
Temozolomide-induced senescent glioblastoma cells exhibit dynamic morphological states with distinct survival mechanisms and drug sensitivities. This heterogeneity and plasticity have direct implications for how chemotherapy resistance develops and why combination senotherapeutic strategies may be necessary to prevent tumor recurrence.
SuperAgers—individuals over 80 with memory performance matching those decades younger—maintain roughly twice the neurogenic capacity of age-matched peers, driven by preserved epigenetic regulation that keeps regenerative neural programs accessible. This finding reframes cognitive aging from inevitable decline to a regulated, potentially modifiable biological process.
Research on killifish demonstrates that aging occurs in discrete stages rather than linear decline, with movement patterns in mid-life serving as a measurable predictor of remaining lifespan. This staged aging model suggests that locomotor capacity reflects underlying systemic vulnerability across multiple organ systems.
Stanford researchers created the first comprehensive atlas of lysosomal proteins across four major brain cell types, revealing cell-specific patterns that explain how waste accumulation contributes to Alzheimer's, Parkinson's, and other neurodegenerative diseases. This cellular-level mapping shifts neurodegeneration research toward early prevention rather than late-stage intervention, with direct implications for maintaining cognitive function across the lifespan.
Adequate hydration is a critical but often overlooked factor in healthy aging. Dehydration impairs multiple physiological systems and accelerates age-related decline, making hydration status a measurable and modifiable component of longevity strategy.
Researchers have mapped 250 genes essential for human muscle fiber formation using a CRISPR screening platform, identifying previously unknown genetic drivers of muscle development and linking 41 of these genes to developmental muscle defects. This foundational knowledge directly informs understanding of sarcopenia and age-related muscle loss, where the same fusion mechanisms that fail in rare genetic disorders deteriorate progressively with age.
João Pedro de Magalhães and Zhuang Zhuang Han have published a peer-reviewed ethical framework addressing persistent public and scientific concerns about longevity science. The paper provides researchers with evidence-informed arguments to address misconceptions about aging intervention—concerns that have remained largely consistent over two decades despite scientific progress.
Lipid mediators in platelet transfusions—particularly lysophosphatidic acid, lysophosphatidylcholine, and sphingosine-1-phosphate—decline with donor age and correlate with adverse transfusion reactions through altered platelet and endothelial cell activation. This finding suggests that donor age-related changes in lipid signaling directly influence transfusion safety and vascular biology.
Severe infections carry independent dementia risk beyond what frailty and comorbidities explain, suggesting infection-related mechanisms directly contribute to cognitive decline. This identifies a modifiable pathway distinct from typical aging trajectories.
FGF21 activates a cellular repair pathway in spinal disc cells by upregulating SIRT1, which deacetylates FOXO3 and triggers mitochondrial autophagy, thereby suppressing cell senescence and slowing intervertebral disc degeneration. This identifies a targetable molecular axis with direct relevance to preventing age-related spinal structural decline and associated disability.
Celularity licensed its placental-derived biomaterials portfolio for up to $35 million in non-dilutive capital, allowing the company to redirect resources toward cell therapies targeting senescence, inflammation, and tissue degeneration. This repositioning reflects a strategic shift from broad biomaterials commercialization to targeted longevity interventions.
